Chemotherapy News and Research

Latest Chemotherapy News and Research

Novel combined immunotherapy promising for treatment of malignant brain tumors

A new Phase I clinical trial conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute in Los Angeles shows that two innovative treatment approaches may safely be combined to treat patients with highly aggressive, malignant brain tumors called gliomas. The results suggest that combining the two therapies might boost their effectiveness and supports the pursuit of additional studies on this approach to treating these tumors.

4 May 2010

Fudged cancer patient waiting times reports, says AMAQ

The Australian Medical Association of Queensland (AMAQ) recently revealed that the state’s health authorities are keeping the truth about waiting time for cancer patients under wraps.

4 May 2010

NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful completion of the first-in-human clinical trial with Spiegelmer® NOX-A12.

3 May 2010

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.

3 May 2010

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents.

3 May 2010

Promising results from combination therapy of pemetrexed concurrent with radiation in lung cancer

The first trial of an important new combination therapy of treatment with the chemotherapy drug pemetrexed concurrent with radiation in lung cancer has delivered promising results, French researchers report at the 2nd European Lung Cancer Conference.

3 May 2010

Parents administering highly complex medication regimens require additional supports

Parents of children with chronic conditions make many mistakes when giving lifesaving medicines, according to a study being presented Monday, May 3 at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.

3 May 2010

BSGI improves breast cancer detection

A new study, presented at the American Society of Breast Surgeons Annual Meeting in Las Vegas, found that Breast-Specific Gamma Imaging (BSGI) is highly accurate in monitoring the response of breast cancers to neoadjuvant chemotherapy.

3 May 2010

FDA oks 'vaccine' to treat prostate cancer

Provenge, developed by Dendreon Corporation, is the first approved "treatment that uses a so-called cancer vaccine, a drug that trains the body's own immune system to fight the disease," The New York Times reports.

3 May 2010

Study indicates older women with diabetes have increase risk for colon cancer

A research team led by Mayo Clinic physicians has found that older women with diabetes face a more than doubled risk for some types of colorectal cancer.

3 May 2010

Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference

Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed oral therapy for advanced non-small cell lung cancer.

3 May 2010

FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer

Tikcro Technologies Ltd. today announced that BioCancell Therapeutics, Inc., concluded the first 18 patient group treated pursuant to a Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer. These patients had not responded to conventional treatment.

3 May 2010

Accelerated radiotherapy improves overall survival of patient with NSCLC: Report

A new meta-analysis reported at the second European Lung Cancer Conference shows that patients with both non-small-cell lung cancer and small-cell lung cancer benefit in terms of overall survival when treated with hyperfractionated or accelerated radiotherapy.

30 Apr 2010

Registration for 2010 Siemens Competition in Math, Science & Technology opens

Starting today, aspiring scientists and mathematicians nationwide can register for the 2010 Siemens Competition in Math, Science & Technology, the premiere original research competition for high school students in the United States. In just six months, submitted projects will be judged and the countdown to the national finals in Washington, D.C. will begin.

30 Apr 2010

Computers may cause physical problems to children: Researchers

Professor Straker said the guidelines were important because computer use by children was extremely high globally and discomfort reported by children using computers was increasing.

30 Apr 2010

ADVENTRX reports first-quarter net loss applicable to common stock of $4.9 million

ADVENTRX Pharmaceuticals, Inc. today reported financial results for the three months ended March 31, 2010.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

Study confirms MammaPrint's capabilities in determining patients likely to benefit from chemotherapy

Today, at the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer Research and Treatment has published an important study demonstrating the benefit of adjuvant chemotherapy for patients with a high-risk of breast cancer recurrence according to the MammaPrint test. The ASBS meeting takes places April 28 - May 2, 2010, at the Bellagio in Las Vegas, where you can meet the Agendia team at booth # 314.

30 Apr 2010

PROVENGE receives FDA approval for treatment of CRPC

Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.

30 Apr 2010

$EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout$

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase‑PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

30 Apr 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Novel combined immunotherapy promising for treatment of malignant brain tumors

Fudged cancer patient waiting times reports, says AMAQ

NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Promising results from combination therapy of pemetrexed concurrent with radiation in lung cancer

Parents administering highly complex medication regimens require additional supports

BSGI improves breast cancer detection

FDA oks 'vaccine' to treat prostate cancer

Study indicates older women with diabetes have increase risk for colon cancer

Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference

FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer

Accelerated radiotherapy improves overall survival of patient with NSCLC: Report

Registration for 2010 Siemens Competition in Math, Science & Technology opens

Computers may cause physical problems to children: Researchers

ADVENTRX reports first-quarter net loss applicable to common stock of $4.9 million

REGN reports net loss of $30.5M for first-quarter 2010

Study confirms MammaPrint's capabilities in determining patients likely to benefit from chemotherapy

PROVENGE receives FDA approval for treatment of CRPC

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

Cancer Research - Second Edition eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Newsletters you may be interested in